Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization.

Department of Communicable Diseases, Imperial College School of Medicine at St. Mary's, London, United Kingdom.
Journal of Virology (Impact Factor: 4.65). 12/1996; 70(11):7827-32.
Source: PubMed

ABSTRACT Human immunodeficiency virus type 1 (HIV-1) primary isolates from four geographical locations in Thailand, Brazil, Rwanda, and Uganda, representing genetic subtypes A, B, C, D, and E, were examined for autologous and heterologous neutralization by panels of human HIV+ polyclonal plasma. In independent linked experiments in three laboratories using diverse methodologies and common reagents, no defined pattern of genetic subtype-specific neutralization was observed. Most plasma tested were broadly cross-neutralizing across two or more genetic subtypes, although the titer of neutralization varied across a wide range. We conclude that the genetic subtypes of HIV-1 are not classical neutralization serotypes.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Soon after HIV was discovered as the cause of AIDS in 1983-1984, there was an expectation that a preventive vaccine would be rapidly developed. In trying to achieve that goal, three successive scientific paradigms have been explored: induction of neutralizing antibodies, induction of cell mediated immunity, and exploration of combination approaches and novel concepts. Although major progress has been made in understanding the scientific basis for HIV vaccine development, efficacy trials have been critical in moving the field forward. In 2009, the field was reinvigorated with the modest results obtained from the RV144 trial conducted in Thailand. Here, we review those vaccine development efforts, with an emphasis on events that occurred during the earlier years. The goal is to provide younger generations of scientists with information and inspiration to continue the search for an HIV vaccine.
    Vaccine 05/2013; 31(35). DOI:10.1016/j.vaccine.2013.05.018 · 3.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Maternal-to-child-transmission of HIV-1 infection remains a significant cause of HIV-1 infection despite successful prevention strategies. Testing protective HIV-1 vaccines remains a critical priority. The immunogenicity of ALVAC-HIV vCP1521 (ALVAC) in infants born to HIV-1 infected women in Uganda was evaluated in the first pediatric HIV-1 vaccine study in Africa. HPTN 027 was a randomized, double blind, placebo-controlled phase I trial to evaluate the safety and immunogenicity of ALVAC in 60 infants born to HIV-1 infected mothers with CD4 counts > 500 cell/μL that were randomized to the ALVAC vaccine or placebo. ALVAC-HIV vCP1521 is an attenuated recombinant canarypox virus expressing HIV-1 clade E env, clade B gag and protease gene products. Infants were vaccinated at birth, 4, 8 and 12 weeks of age with ALVAC or placebo. Cellular and humoral immune responses were evaluated using IFN-γ ELISpot, CFSE proliferation, intracellular cytokine staining, binding and neutralizing antibody assays. Fisher's exact test was used to compare positive responses between study arms. Low levels of antigen specific CD4 and CD8 T cell responses (intracellular cytokine assay) were detected at 24 months (CD4 - 6/36 vaccine vs. 1/9 placebo; CD8 - 5/36 vaccine vs. 0/9 placebo) of age. There was a non-significant trend toward higher cellular immune response rates in vaccine recipients compared to placebo. There were minimal binding antibody responses and no neutralizing antibodies detected. HIV-1 exposed infants are capable of generating low levels of cellular immune responses to ALVAC vaccine, similar to responses seen in adults.
    JAIDS Journal of Acquired Immune Deficiency Syndromes 10/2013; 65(3). DOI:10.1097/01.qai.0000435600.65845.31 · 4.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Data on humoral immune response against Brazilian human immunodeficiency virus type 1 (HIV-1) isolates have been collected and reviewed in reference to data published in the international literature. The results obtained up to now indicate that the Brazilian humoral immune response can be divided into at least three antibody binding serotypes: anti-Bbr, anti -B/F and anti-C/F. No neutralization serotypes have been distinguished up to now, just different degrees of resistance to neutralizing antibody (NAb), similar to data obtained by neutralization analyses of European/North American HIV-1isolates. No correlation between V3 binding antibodies, genotype and HIV-1 NAb could be observed.
    Clinical and Applied Immunology Reviews 05/2003; 3(6):307-317. DOI:10.1016/S1529-1049(03)00002-3

Full-text (2 Sources)

Available from
Oct 3, 2014